Loading
A phase 1/2 trial of Golidocitinib in peripheral T-cell lymphomas, run by Dizal Pharmaceuticals, now recruiting.
Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3) is a phase 1/2 interventional study registered as NCT07496229 by Dizal Pharmaceuticals, with 165 participants planned, started 2026-04-15 and due to reach its primary completion in 2029-09. Interventions recorded: GW5282 combined with Golidocitinib and Conventional CHOP regimen.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Golidocitinib, Dizal Pharmaceutical, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Small-molecule kinase inhibitors.
Shares Dizal Pharmaceutical and the tag pipeline.
Shares Dizal Pharmaceutical, Small-molecule kinase inhibitors and the tag pipeline.
Shares Dizal Pharmaceutical and the tag pipeline.
Shares Dizal Pharmaceutical and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/